Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Oral Contraceptive Use in EOC Patients

Study looks at survival rates

In patients with epithelial ovarian cancer (EOC), the use of oral contraceptives may have lasting effects on tumor characteristics, and potentially favorable prognosis on overall survival, according to a cohort study of 387 women with newly diagnosed EOC, fallopian tube, and primary peritoneal cancers. The study concluded:

• Decreased risk of death was observed in women who reported prior use of OC (aHR=0.79), previous pregnancy (aHR=0.77), or a live birth (aHR=0.81) after adjusting for age at diagnosis, stage and histologic subtype.

• OC use was associated with a crude reduced risk of death (HR=0.55) with reported median overall survival of 81 months in OC users vs. 46 months in nonusers.

• Patients who reported a single live birth experienced the largest potential survival advantage (aHR=0.61).

• OC use and prior pregnancy were associated with improved survival across all strata.

Citation: Kolomeyevskaya NV, Szender JB, Zirpoli G, et al. Oral contraceptive use and reproductive characteristics affect survival in patients with epithelial ovarian cancer: A cohort study. Int J Gynecol Cancer. [Published online ahead of print August 13, 2015]. doi: 10.1097/IGC.0000000000000540.